baber/WOPTO huggingface dataset:
Patent NZ-551680-A (NZ)
Title: Quinazolinone derivatives as PARP inhibitors
Inventor: GUILLEMONT JEROME EMILE GEORGES
IPC: C07D239/90
Filed: 2005-06-28
Abstract: Disclosed is a compound of formula (I), or an N-oxide, pharmaceutically acceptable addition salt, or stereochemically isomeric form thereof, wherein: the dotted lines represent optional bonds; X is >N- or >CH-; -N-Y- is ûN-C(O)- or ûN=C(OH)-; L is a bond, -C(O)-, -C(O)NH-, -NH-, -C(O)-C1-6alkanediyl-, -C(O)OC1-6alkanediyl-, or ûC1-6alkanediyl-; R2 is hydrogen, hydroxy, C1-6alkyloxy, or aminocarbonyl, or when X is substituted with R2 then R2 and ûL-Z may form a bivalent radical ûC(O)-NH-CH2-NPh-; and wherein the other substituents are as described in the specification. Also disclosed is the use of the compound for treating a PARP mediated disorder, for treating cancer, and its use with a chemotherapeutic agent. Also disclosed is a process for preparing the compound.
Patent NZ-554861-A (NZ)
Title: Plate for producing an electroluminescent number plate
Inventor: SAUER ARNO MARTIN
IPC: B60R13/10
Filed: 2005-10-04
Abstract: Disclosed is a plate for producing an electroluminescent number plate. The plate has an inscription area and a border area which lies outside the inscription area. The plate includes a board and a film. The film has an electroluminescent coating and extends at least partially over the inscription area and the border area. The film includes metallic conductor tracks which are electrically insulated from the board.
Patent NZ-566408-A (NZ)
Title: Prophylactic and therapeutic agents Ndfip1 and Nedd4 and uses therefor
Inventor: TAN SEONG-SENG
IPC: A61P27/00
Filed: 2006-09-01
Abstract: Disclosed is the use of Ndfip1 or Nedd4 or a nucleic acid molecule encoding Ndflp1 or Nedd4 in the manufacture of a medicament in the treatment of a neurological condition selected from trauma to the brain, a severe head injury, trauma-induced paralysis, infection and starvation and hypoxia in preterm infants or in the retina of an eye of a subject. Also disclosed is a method for determining the presence of a neurological condition selected from trauma to the brain, a severe head injury, trauma-induced paralysis, infection and starvation and hypoxia in preterm infant or in the retina of an eye of a subject said method comprising determining the levels of Ndfip1 or Ndflp1-expression or Ndflp1-Nedd4 interaction in an in vitro sample.
Patent NZ-567190-A (NZ)
Title: Method of producing a recombinant protein comprising transforming an E. Coli host cell lacking a gene encoding pyrC with a vector comprising a gene encoding the recombinant protein and a gene encoding E. coli pyrC
Inventor: MARTIN FRANCK
IPC: C12N15/68
Filed: 2006-10-04
Abstract: Disclosed is a method of producing a recombinant protein comprising: (a) transforming an E. coli host cell lacking a gene encoding pyrC or a homologue thereof having at least 70% identity to pyrC, with a vector comprising a gene encoding the recombinant protein and a gene encoding E. coli pyrC; and (b) growing said E. coli host cell under conditions of pyrimidine limitation, provided that said host cell is not within a human.
Patent NZ-570477-A (NZ)
Title: Medical adhesive and methods of tissue adhesion
Inventor: BECKMAN ERIC J
IPC: A61L24/04
Filed: 2007-01-26
Abstract: Disclosed is the use of a biodegradable, moisture-curable isocyanate-functional composition in the manufacture of an adhesive for adhering biological tissue, the isocyanate functional composition comprising the reaction product of: (a) a multi-functional isocyanate component having an average functionality of h, wherein h is at least 2; and (b) a multi-functional active hydrogen component comprising at least 30 percent by weight, based upon the total weight of the multi-functional active hydrogen component, of a multi-functional active hydrogen reactant having an equivalent weight (equivalent weight divided by hydroxyl functionality) less than 100, wherein a ratio R of active hydrogen groups to isocyanate groups is selected such that l/h <R < 0.9.
Patent NZ-572258-A (NZ)
Title: Use of arylcarboxylic acid biphenylamides for seed treatment
Inventor: DIETZ JOCHEN
IPC: A01N43/653
Filed: 2007-05-02
Abstract: Disclosed is a method for protecting plants after germination from the attack of foliar phytopathogenic fungi, which comprises treating the seed from which the plants are to grow with an effective amount of at least one arylcarboxylic acid of a biphenylamide of the formula I. Wherein X is halogen or methyl; n is zero, 1 or 2; Y is cyano, nitro, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylthio, haloalkylthio, alkoxy-iminomethyl or allyloxyiminomethyl; m is zero to 5 and Ar is defined in the specification or with an agriculturally acceptable salt thereof.
Patent NZ-572302-A (NZ)
Title: Apnea respirator conduit with air flow controllers and dead space volumes
Inventor: DALY ROBERT W
IPC: A61M16/08
Filed: 2007-04-17
Abstract: A system for controlling the breathing of a patient includes a respiratory conduit 120 that is interspersed between the patient interface 102 (mask) and the pressurised air generator 130. The conduit 120 includes at least three air flow control devices 108, 112, 114 between the patient mask and the air generator with each pair of the air flow control devices being separated by respective gas volumes 111, 113 which act as partial dead space volumes which can accumulate a portion of the breath expired by the patient. The volumes together with the air flow control devices control the rate of excretion of gas from the respirator conduit, the concentration of gas in the blood of the patient.
Patent NZ-578747-A (NZ)
Title: Kayak outboard outrigger mount
Inventor: CARTER WAYNE
IPC: B63B35/71
Filed: 2009-07-30
Abstract: An outrigger assembly 20 for use with a vessel, comprises an elongate bar 121, two male members 122 engaged with the elongate bar 121 and capable of rotary movement in all directions with respect to it, and a float connected to the elongate bar 121 distal from the two mail members 122. The two male members 122 are adapted to co-operate with corresponding female members of the vessel. The float may be positioned to enhance vessel stabilisation on water.
Patent NZ-580932-A (NZ)
Title: Flexible spring connector with a helix body with a tapered internal circumference
Inventor: MOORE SIMON GARRY
IPC: F16B2/24
Filed: 2010-11-02
Abstract: Disclosed is a connector in the form of a spring type fastener. The connector has a body having a helix (1) configured to change circumferentially in response to a change in force applied to the connector. The helix has at least one portion with a reduced circumference. The external (3) and internal surfaces of the helix are configured to have a substantially planar contact surface. At least part of the body (2) is hollow in an axial direction, and a portion of the internal circumference of the hollowed body is tapered.
Patent NZ-581960-A (NZ)
Title: Hmpsa for removable self-adhesive label
Inventor: FOUQUAY STEPHANE ANDRE
IPC: C08K5/09
Filed: 2008-06-26
Abstract: Disclosed herein is a hot-melt pressure-sensitive adhesive (HMPSA) composition comprising: · 20 to 50% of one or more styrene block copolymers chosen from the group comprising SIS (polystyrene / polyisoprene / polystyrene), SIBS (polystyrene / polyisoprene/ polybutadiene /polystyrene), SEBS (polystyrene / poly(ethylenebutylene) / polystyrene), and SEPS (polystyrene / poly(ethylenepropylene) / polystyrene) block copolymers optionally blended with an amount of an SBS (polystyrene / polybutadiene / polystyrene) styrene block copolymer of less than 50% on the basis of the total weight of the styrene block copolymers; · 35 to 75% of one or more compatible tackifying resins having a softening temperature of between 80 and 150°C and an acid number of less than 20; and · 0.5 to 20% of one or more carboxylic acids, such as (a) saturated or unsaturated, monocarboxylic fatty acids, whether pure or as mixtures; (b) mixtures of saturated or unsaturated polycyclic fatty acids of the dimmer or trimer type; and (c) mixtures of saturated or unsaturated polycyclic monocarboxylic acids; wherein the hydrocarbon chain of which comprises 6 to 54 carbon atoms. Also disclosed is a multilayer system comprising the adhesive layer as defined above, a printable support layer adjacent to said adhesive layer, consisting of paper or polymer film having one or more layers, and a protective layer adjacent to said adhesive layer.
Patent NZ-582225-A (NZ)
Title: A method of drilling and completing a well with sandscreens and drilling fluid
Inventor: BRADBURY ANDREW
IPC: E21B43/08
Filed: 2008-05-07
Abstract: Disclosed is a method for drilling and completing a wellbore (32). The wellbore is drilled through a subterranean formation using a wellbore fluid comprising a base fluid and a micronized weighting agent. A sand screen is then disposed between the pipe ends and the desired substance to be extracted.
Patent NZ-584034-A (NZ)
Title: Regional oxygen uptake/perfusion measuring device and method utilising electrical impedance tomography
Inventor: WEILER NORBERT
IPC: A61B5/05
Filed: 2008-09-09
Abstract: Disclosed is a means for assessing regional oxygen uptake or perfusion in a patient, comprising: i. means for determining a volume of air inhaled by the patient; ii. means for measuring according to a method of electrical impedance tomography a first regional lung volume at a first time point of a breathold procedure; and iii. means for comparing the first regional lung volume to a second regional lung volume at a second time point of the breathold procedure.
Patent NZ-585880-A (NZ)
Title: Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
Inventor: KESHAVARZ-SHOKRI ALI
IPC: A61P11/00
Filed: 2008-12-04
Abstract: Disclosed is a crystalline polymorph of 3-(6-(1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, characterized by XRPD as Form I, and a method for its preparation. Form I is characterized by one or more peaks at 15.2 to 15.6 degrees, 16.1 to 16.5 degrees, and 14.3 to 14.7 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation. The crystalline polymorph is useful for treating cystic fibrosis.
Patent NZ-589962-A (NZ)
Title: Inhibitors of stearoyl-CoA desaturase and uses thereof
Inventor: DALES NATALIE
IPC: C07D213/81
Filed: 2009-06-25
Abstract: The present disclosure provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed. Examples of the disclosed compounds include: 2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-N-methylisonicotinamide, 2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-N-((5-methylpyrazin-2-yl)methyl)isonicotinamide, N-((1,5-dimethyl-1H-pyrazol-3-yl)methyl)-2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)isonicotinamide, N-(3,4-difluorobenzyl)-2-(2-oxo-3-(pyridin-2-ylmethyl)imidazolidin-1-yl)isonicotinamide, N-((5-methylisoxazol-3-yl)methyl)-2-(2-oxo-3-(4-(trifluoromethoxy)-benzyl)imidazolidin-1-yl)isonicotinamide, 2-(2-oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)-N-(thiazol-5-ylmethyl)-isonicotinamide and N-((2-chlorothiazol-5-yl)methyl)-2-(3-(3,4-difluorobenzyl)-2-oxoimidazolidin-1-yl)isonicotinamide.
Patent NZ-592830-A (NZ)
Title: Process for the modulation of the antagonistic activity of a monoclonal antibody
Inventor: GOETSCH LILIANE
IPC: C07K16/00
Filed: 2009-12-02
Abstract: 592830 Disclosed is a process of improving the antagonistic activity of a monoclonal antibody directed against a specific target molecule, or a divalent functional fragment or derivative thereof, said antibody being capable of inhibiting one or more of the biological activities of said target molecule, wherein said process comprises a stage of reconfiguration of the hinge region consisting of a modification of the amino acid sequence of said hinge region by the deletion, the addition or the substitution of at least one amino acid and wherein said reconfigured hinge region has a sequence selected from the group consisting of PRDCGCKPCICT, PKSCGCKPCICT, PKSCGCKPCICP, PRDCGCKPCPPCP, PRDCGCHTCPPCP, PKSCDCHCPPCP, RKCCVECPPCP, CKSCDKTHTCPPCP, PCSCDKTHTCPPCP, PKCCDKTHTCPPCP, PKSCCKTHTCPPCP, PKSCDCTHTCPPCP, PKSCDKCHTCPPCP, PKSCDKTCTCPPCP, PKSCDKTHCCPPCP, PSCDKTHTCPPCP, PKSCDTHTCPPCP, PKSCDKTHCPPCP, KCDKTHTCPPCP, PSCKTHTCPPCP, PKSCDTHCPPCP, PKSCTHTCPPCP, PKSCDKTHCPPC, PKSCDCHTCPPCP, PKSCDCTHCPPCP, PCSCKHTCPPCP, PSCCTHTCPPCP, PSCDKHCCPPCP, PKSTHTCPPCP, PKSCTCPPCP and PKSCDKCVECPPCP Further disclosed are monoclonal antibodies according the above process, characterized in that it comprises an amino acid sequence selected from the group consisting of PKSCGCKPCICT, PKSCGCKPCICP, PRDCGCKPCPPCP, PRDCGCHTCPPCP, PKSCDCHCPPCP, CKSCDKTHTCPPCP, PCSCDKTHTCPPCP, PKCCDKTHTCPPCP, PKSCCKTHTCPPCP, PKSCDCTHTCPPCP, PKSCDKTCTCPPCP, PKSCDKTHCCPPCP, PSCDKTHTCPPCP, PKSCDTHTCPPCP, PKSCDKTHCPPCP, KCDKTHTCPPCP, PSCKTHTCPPCP, PKSCDTHCPPCP, PKSCTHTCPPCP, PKSCDKTHCPPC, PKSCDCHTCPPCP, PKSCDCTHCPPCP, PCSCKHTCPPCP, PSCCTHTCPPCP, PSCDKHCCPPCP, PKSTHTCPPCP, PKSCTCPPCP and PKSCDKCVECPPCP
Patent NZ-598686-A (NZ)
Title: Rapid establishment and/or termination of substantial steady-state drug delivery
Inventor: ALESSI THOMAS R
IPC: C12Q1/68
Filed: 2010-09-21
Abstract: The disclosure relates to the use of an exenatide for the manufacture of a medicament for treating type 2 diabetes mellitus in a human by a method comprising: providing continuous delivery of the exenatide from an osmotic delivery device comprising: (1) an impermeable reservoir comprising interior and exterior surfaces and first and second open ends; (2) a semi-permeable membrane in sealing relationship with the first open end of the reservoir; (3) an osmotic engine within the reservoir and adjacent the semi-permeable membrane; (4) a piston adjacent the osmotic engine, wherein the piston forms a movable seal with the interior surface of the reservoir and divides the reservoir into a first chamber and a second chamber, the first chamber comprising the osmotic engine and the second chamber comprising a suspension formulation; and (5) a diffusion moderator inserted in the second open end of the reservoir, the diffusion moderator adjacent the suspension formulation, the suspension formulation comprising a particle formulation and a vehicle formulation, the particle formulation comprising particles comprising exenatide in particles of less than 10 microns in diameter and the vehicle formulation comprising: a solvent selected from the group consisting of benzyl benzoate, lauryl lactate, and lauryl alcohol, and (b) a polymer that is polyvinylpyrrolidone, the vehicle formulation having a viscosity between about 10,000 poise and about 20,000 poise at 37 degrees Celsius; wherein substantial steady-state delivery of the exenatide at a therapeutic concentration is achieved within a time period of 5 days or less after implantation of the osmotic delivery device in the human and the substantial steady-state delivery of the exenatide from the osmotic delivery device is continuous over an administration period of at least 3 months at a mcg/day dose of the exenatide selected from the group consisting of about 10 mcg/day, about 20 mcg/day, about 30 mcg/day, about 40 mcg/day, about 60 mcg/day, and about 80 mcg/day.
Patent NZ-598923-A (NZ)
Title: Dicyclanil-based aqueous suspension and non-aqueous solution pour-on and spray on formulations for the prevention and treatment of insect infestation in animal
Inventor: RAZZAK MAJID
IPC: A61K9/00
Filed: 2010-09-21
Abstract: 598923 Disclosed is a topically acceptable aqueous formulation adapted to be applied externally to an animal, which formulation comprises dicyclanil, a hydrophilic surfactant selected from a biopolymer, a suspending agent, an aromatic alcohol, a buffering agent, an anti -caking agent, citric acid and water.
Patent NZ-601470-A (NZ)
Title: Use of polyethylenimines as an additive for maintaining a stable conductivity in aqueous suspensions of calcium carbonate-comprising materials
Inventor: BURI MATTHIAS
IPC: C09C1/02
Filed: 2011-01-24
Abstract: ABSTRACT - 601470 Disclosed herein is a use of at least one polyethylenimine as an additive in an aqueous suspension, containing from 25 to 62 vol. %, based on the total volume of the suspension, of at least one calcium carbonate-comprising material and having a pH of between 8.5 and 11, for increasing the suspension pH by at least 0.3 pH units, wherein the suspension conductivity change is not more than 100 (S/cm per pH unit, the at least one polyethylenimine (preferably selected from triethylenetetramine, pentaethylenehexamine and tetraethylenepentamine) is added to said suspension in an amount of from 500 to 15000 mg, per liter of the aqueous phase of said suspension. Said aqueous suspension containing a polyethylenimine is used in in paint and/or paper applications.
Patent NZ-603648-A (NZ)
Title: Methods of purifying polypeptides
Inventor: MCCOOEY BETH
IPC: G01N31/00
Filed: 2011-05-25
Abstract: Disclosed is a method for purifying an antibody or immunoadhesin from a composition comprising the antibody or immunoadhesin and at least one contaminant, wherein the method comprises either (i) or (ii): (i) sequential steps of (a) loading the composition onto a cation exchange material at a loading density of greater than about 150 g/L of cation exchange material; and (b) loading a composition recovered from the cation exchange material onto a mixed mode material; or (ii) sequential steps of (a) loading the composition onto a mixed mode material; and (b) loading a composition recovered from mixed mode material onto a cation exchange material at a loading density of greater than about 150 g/L of cation exchange material.
Patent NZ-603721-A (NZ)
Title: Process of producing cycloalkylcarboxamido-indole compounds
Inventor: LITTLER BENJAMIN JOSEPH
IPC: C07D405/12
Filed: 2011-04-21
Abstract: Disclosed herein is a method for preparing cycloalkylcarboxamido-indole compounds which are useful for treating CFTR mediated diseases such as cystic fibrosis. In particular a method of preparing a compound of formula I comprising the steps of: Reacting a compound of formula IA in a first organic solvent with a compound of formula IB; to form a compound of formula IC in the presence of a palladium catalyst; and Removing the –CO2RJ group from compound IC in a second organic solvent to form the compound of formula I.
Patent NZ-608826-A (NZ)
Title: Improvements in and relating to agitator systems
Inventor: REID PETER JOHN KENNETH
IPC: C02F103/20
Filed: 2012-03-26
Abstract: An agitator system for mixing slurry, said slurry being contained in a slurry pond. The agitator system including at least one agitator assembly and a support assembly. Each agitator assembly is associated with at least two, diametrically opposed, impellers. The support assembly supports each agitator assembly relative to the slurry. Each agitator assembly including a drive assembly, the drive assembly including a lower section associated with the impellers. The lower section being adapted to rotate to set positions through a range of 360 degrees (B1, B2). The agitator assembly may be height adjustable, and wholly or partly submersible. At least one drive shaft may be substantially vertical and driven by a drive means e.g. a hydraulic or electric motor means. The impellers may rotate at an angle between 0-90 degrees to the drive shaft, either angled upwards or downwards. The angle of at least one impeller may be adjustable (D). The impeller(s) may comprise a propeller, the propeller may be designed for the slurry being mixed.
Patent NZ-611951-A (NZ)
Title: Calicheamicin derivative-carrier conjugates
Inventor: MORAN JUSTIN KEITH
IPC: C12N15/63
Filed: 2003-05-02
Abstract: Disclosed is a method for preparing a composition with reduced low conjugated fraction (LCF) below 10% comprising monomeric calicheamicin derivative/antibody conjugates having the formula, Pr(-X-W)m wherein: Pr is an antibody; X is a hydrolyzable linker having the formula (CO-Alk1-sp1-Ar-sp2-Alk2-C(Z1)=Q-Sp) as defined herein; the method comprising the steps of: (1) adding the calicheamicin derivative to the antibody wherein the calicheamicin derivative is 4.5-11% by weight of the antibody; (2) incubating the calicheamicin derivative and the antibody in a non-nucleophilic, protein-compatible, buffered solution having a pH in the range from about 7 to 9 to produce a monomeric calicheamicin derivative/antibody conjugate, wherein the solution further comprises (a) an organic cosolvent, and (b) an additive comprising 5 at least one C6-C18 carboxylic acid or its salt, and wherein the incubation is conducted at a temperature ranging from about 30°C to about 35°C for a period of time ranging from about 15 minutes to 24 hours; and (3) subjecting the conjugate produced in step (2) to a chromatographic separation process to separate monomeric calicheamicin derivative/antibody conjugates with a loading in the range of 4-10% by weight calicheamicin and with low conjugated fraction (LCF) below 10 percent from unconjugated antibody, calicheamicin derivative, and aggregated conjugates. Further disclosed are compositons with reduced low conjugated fraction (LCF) below 10 percent comprising monomeric calicheamicin derivative/anti-CD22 antibody conjugates having the formula, Pr(-X-W)m wherein: Pr is an anti-CD22 antibody; X is a hydrolyzable linker having the formula (CO-Alk1-sp1-Ar-sp2-Alk2-C(Z1)=Q-Sp) as defined herein.
Patent NZ-624353-A (NZ)
Title: Facility for processing stacked flat on-edge objects, method for loading stacked flat on-edge objects
Inventor: CARON ARNAUD
IPC: B65H31/06
Filed: 2012-11-14
Abstract: A facility (1) for processing flat objects (2, 3) stacked on-edge, such as mail. A transport trolley (300) is provided with an inclined bottom wall (307) for bringing the articles (2, 3) to bear against an end wall (306) of the trolley. An opening (304) is provided opposite the end wall (306) for loading. The trolley (300) transports articles (2, 3) between first (see Fig. 1, 100) and second (200) storage units which respectively have a loading area (see Fig. 1, 101) and a storage area (201). An unloading area (203) is provided upstream from the storage area (201) and is movable between a transfer position (shown) where it is coplanar with the storage area (201) and an unloading position (see Fig. 4) where it is coplanar with the bottom wall (307) of the cart (300).